Following the announcement, the Company will host a live teleconference and webcast at
The press release and the live webcast of the conference call will be available in the investor section of
To participate in the live conference call, please dial (833) 652-5917 (
About
Forward-Looking Statements
This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the
Contact:
Tel: +44 1235 430 583
Email: Sebastien.Desprez@adaptimmune.com
(C) 2020 Electronic News Publishing, source